Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer

Study Summary

This is a French, nationwide, prospective, observational, multi-center study in participants diagnosed with advanced renal cell carcinoma, who start a new systemic therapy with nivolumab with or without ipilimumab for the first time and within the market authorization approval.

Conditions

Renal Cell Carcinoma Renal Cell Cancer Adenocarcinoma Of Kidney Adenocarcinoma, Renal Cell Kidney Cancer Cancer of the Kidney

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment600 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.746034+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.